by Mark Curtis | Jun 24, 2015
. Welcome to your Update from the Clinic for the month of May. StemCells announced positive topline results from a Phase I/II study in spinal cord injury. Kite Pharma treated its first patient in a Phase I/II study investigating an anti-CD19 CAR T construct in...
by Mark Curtis | Jun 22, 2015
. Welcome to your deal review for the month of May. Juno Therapeutics was active, forming a strategic research collaboration with Fate Therapeutics and acquiring Stage Cell Therapeutics. Adaptimmune decided it would take advantage of the ongoing initial public...
by Stacey Johnson | Jun 19, 2015
.Today is a big day for the regenerative medicine (RM) community in Ontario, Canada. Minister of Research and Innovation, Reza Moridi, just announced that the Ontario Institute for Regenerative Medicine (OIRM) will receive a new $25 million commitment* (in addition to...
by Hamideh Emrani | Jun 8, 2015
. Some of my fond memories of childhood are from the times that my great grandma and grandpa visited us. They told us sweet stories and shared memories of much simpler times. But they had worries too. I vividly remember that one of my great grandmother’s main fears...
by Mark Curtis | May 27, 2015
. Welcome to your deal review for the month of April. There is no update yet on the fate of the Cellular Dynamics International/Fujifilm deal, but it appears that CDI made some effort to solicit offers from alternative bidders. Aduro made headlines, though, closing a...
by Mark Curtis | May 25, 2015
. Welcome to your Update from the Clinic for the month of April. Mesenchymal stem cells took a hit as Athersys’ MultiStem came up short, missing its primary endpoint in a Phase 2 study investigating the cells for ischemic stroke. Juno Therapeutics continues to turn...
Comments